IP Library › Granted Patent US 11,492,392
Granted Patent B2
US 11,492,392 · App. 16/819,977 · Granted Nov 8, 2022

Polynucleotides encoding anti-C5 antibodies

Inventors: Ying Hu (Scarsdale, NY); Adrianna Latuszek (Sleepy Hollow, NY); Carmelo Romano (Tarrytown, NY); William Olson (Yorktown Heights, NY)
Assignee: Regeneran Pharmaceuticals, Inc.
C07K16/18A61K39/3955A61K45/06A61K2039/505A61K2039/54C07K2317/21C07K2317/33C07K2317/34C07K2317/51C07K2317/515C07K2317/565C07K2317/76C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,492,392
App. No.
16/819,977
Granted
Nov 8, 2022
Kind
B2
Abstract

The present invention provides monoclonal antibodies that bind to the complement factor 5 (C5) protein, and methods of use thereof. In various embodiments of the invention, the antibodies are fully human antibodies that bind to C5 protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing C5 activity, thus providing a means of treating or preventing a C5-related disease or disorder in humans. In some embodiments, the invention provides for an anti-C5 antibody that has improved pharmacokinetic and pharmacodynamic properties, e.g., a half-life of more than 10 days.

Claims (42)

1. An isolated polynucleotide molecule comprising a nucleotide sequence that encodes a heavy chain variable region of an antibody or antigen-binding fragment thereof that binds specifically to C5 comprising

a HCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 100;

a HCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 102; and

a HCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 104.

2. An isolated polynucleotide molecule comprising a nucleotide sequence that encodes a light chain variable region of an antibody or antigen-binding fragment thereof that binds specifically to C5 comprising

a LCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 108;

a LCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 110; and

a LCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 112.

3. A vector comprising the polynucleotide of claim 1 .

4. A cell comprising the vector of claim 3 .

5. An isolated polynucleotide molecule comprising a nucleotide sequence that encodes a heavy chain variable region of an antibody or antigen-binding fragment thereof that binds specifically to C5 comprising

a HCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 100,

a HCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 102, and

a HCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 104;

and a light chain variable region of an antibody or antigen-binding fragment thereof that binds specifically to C5 comprising

a LCDR1 that comprises the amino acid sequence set forth in SEQ ID NO: 108,

a LCDR2 that comprises the amino acid sequence set forth in SEQ ID NO: 110, and

a LCDR3 that comprises the amino acid sequence set forth in SEQ ID NO: 112.

6. The isolated polynucleotide molecule of claim 5 , wherein:

the HCDR1 is encoded by a nucleotide sequence as set forth in SEQ ID NO: 99,

the HCDR2 is encoded by a nucleotide sequence as set forth in SEQ ID NO: 101,

the HCDR3 is encoded by a nucleotide sequence as set forth in SEQ ID NO: 103,

the LCDR1 is encoded by a nucleotide sequence as set forth in SEQ ID NO: 107,

the LCDR2 is encoded by a nucleotide sequence as set forth in SEQ ID NO: 109, and

the LCDR3 is encoded by a nucleotide sequence as set forth in SEQ ID NO: 111.

7. The isolated polynucleotide molecule of claim 5 , wherein the antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence as set forth in SEQ ID NO: 98.

8. The isolated polynucleotide molecule of claim 7 , wherein the heavy chain variable region is encoded by a nucleotide sequence as set forth in SEQ ID NO: 97.

9. The isolated polynucleotide molecule of claim 5 , wherein the antibody or antigen-binding fragment comprises a light chain variable region comprising an amino acid sequence as set forth in SEQ ID NO: 106.

10. The isolated polynucleotide molecule of claim 9 , wherein the light chain variable region is encoded by a nucleotide sequence set forth in SEQ ID NO: 105.

11. The isolated polynucleotide molecule of claim 5 , wherein the antibody or antigen-binding fragment comprises a heavy chain variable region comprising an amino acid sequence as set forth in SEQ ID NO: 98; and a light chain variable region comprising an amino acid sequence as set forth in SEQ ID NO: 106.

12. The isolated polynucleotide molecule of claim 11 , wherein the heavy chain variable region is encoded by the nucleotide sequence as set forth in SEQ ID NO: 97; and the light chain variable region is encoded by a nucleotide sequence as set forth in SEQ ID NO: 105.

13. The isolated polynucleotide molecule of claim 11 , wherein the antibody or antigen-binding fragment comprises a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 353.

14. The isolated polynucleotide molecule of claim 11 , wherein the antibody or antigen-binding fragment comprises a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 354.

15. The isolated polynucleotide molecule of claim 11 , wherein the antibody or antigen-binding fragment comprises a heavy chain comprising an amino acid sequence as set forth in SEQ ID NO: 353; and a light chain comprising an amino acid sequence as set forth in SEQ ID NO: 354.

16. A vector comprising the polynucleotide molecule of claim 7 .

17. A vector comprising the polynucleotide molecule of claim 9 .

18. A vector comprising the polynucleotide molecule of claim 11 .

19. A vector comprising the polynucleotide molecule of claim 15 .

20. A cell comprising the vector of claim 16 .

21. A cell comprising the vector of claim 17 .

22. A cell comprising the vector of claim 18 .

23. A cell comprising the vector of claim 19 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2020
From: HU, YING; LATUSZEK, ADRIANNA; ROMANO, CARMELO; OLSON, WILLIAM
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 053171/0866 →
Continuity (5)
Division 15621689 · Jun 13, 2017
Provisional Application 62422107 · Nov 15, 2016
Provisional Application 62405561 · Oct 7, 2016
Provisional Application 62349705 · Jun 14, 2016
Related Publication 20200262900A1 · Aug 20, 2020
Cited By (1)
US 12,527,823